Medpace Holdings Inc - Asset Resilience Ratio
Medpace Holdings Inc (MEDP) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Medpace Holdings Inc (MEDP) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2017)
This chart shows how Medpace Holdings Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Medpace Holdings Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Medpace Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Medpace Holdings Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.00K | 0.0% |
| Total Liquid Assets | $7.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Medpace Holdings Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Medpace Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Medpace Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Medpace Holdings Inc (2014–2017)
The table below shows the annual Asset Resilience Ratio data for Medpace Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $7.00K | $950.72 Million | -0.03pp |
| 2016-12-31 | 0.03% | $308.00K | $979.11 Million | -0.26pp |
| 2015-12-31 | 0.29% | $2.86 Million | $984.04 Million | +0.19pp |
| 2014-12-31 | 0.10% | $1.10 Million | $1.10 Billion | -- |
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medica… Read more